Renaissance Technologies LLC Acquires 26,500 Shares of Surrozen, Inc. $SRZN

Posted by Stanley Muller on Aug 13th, 2026

Renaissance Technologies LLC boosted its holdings in Surrozen, Inc. (NASDAQ:SRZN – Free Report) by 117.1% in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 49,126 shares of the company’s stock after buying an additional 26,500 shares during the quarter. Renaissance Technologies LLC’s holdings in Surrozen were worth $1,431,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of SRZN. Empery Asset Management LP bought a new position in Surrozen in the fourth quarter valued at about $2,350,000. 5AM Venture Management LLC raised its holdings in Surrozen by 25.0% during the 4th quarter. 5AM Venture Management LLC now owns 387,500 shares of the company’s stock worth $8,758,000 after purchasing an additional 77,500 shares during the last quarter. Spruce Street Capital LP bought a new stake in Surrozen during the 4th quarter worth about $9,764,000. 683 Capital Management LLC acquired a new position in Surrozen during the 4th quarter valued at about $949,000. Finally, Jane Street Group LLC bought a new position in shares of Surrozen in the 4th quarter valued at about $624,000. Institutional investors own 66.57% of the company’s stock.

Insider Buying and Selling

In other Surrozen news, major shareholder Tcg Crossover Gp Ii, Llc sold 325,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 22nd. The stock was sold at an average price of $21.25, for a total value of $6,906,250.00. Following the sale, the insider owned 574,047 shares in the company, valued at approximately $12,198,498.75. The trade was a 36.15% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 31.74% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on SRZN shares. HC Wainwright reiterated a “buy” rating and set a $44.00 price target on shares of Surrozen in a research report on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Surrozen in a research note on Friday, July 17th. Zacks Research raised shares of Surrozen from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 28th. Finally, TD Cowen started coverage on Surrozen in a research note on Tuesday, April 21st. They issued a “buy” rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Surrozen has a consensus rating of “Moderate Buy” and an average target price of $42.00.

View Our Latest Research Report on SRZN

Surrozen Stock Down 3.4%

Shares of NASDAQ:SRZN opened at $24.19 on Thursday. The firm has a market cap of $280.85 million, a price-to-earnings ratio of -0.60 and a beta of 0.52. Surrozen, Inc. has a 12 month low of $10.06 and a 12 month high of $35.00. The company’s fifty day simple moving average is $22.90 and its 200 day simple moving average is $25.53.

Surrozen (NASDAQ:SRZN – Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.29) by $0.88. The firm had revenue of $5.00 million for the quarter, compared to the consensus estimate of $0.47 million. Research analysts expect that Surrozen, Inc. will post -7.62 earnings per share for the current fiscal year.

About Surrozen

(Free Report)

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.